Ceftazidime -avibactam

DRUG2 trials

Sponsors

Pfizer

Conditions

Complicated Intra-abdominal InfectionsComplicated Urinary Tract Infections

Phase 2

Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

CompletedNCT02475733

PfizerComplicated Intra-abdominal Infections

Start: 2015-08-01End: 2017-06-01Updated: 2018-08-09

Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)

CompletedNCT02497781

PfizerComplicated Urinary Tract Infections

Start: 2015-09-24End: 2017-09-15Updated: 2018-07-11

Related Papers

Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime‐Avibactam in Pediatric Patients Aged 3 Months and Older

Clinical Pharmacology & Therapeutics2021-10-2328 citations

Safety and Efficacy of Ceftazidime–Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial

The Pediatric Infectious Disease Journal2019-07-2168 citations

Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial

The Pediatric Infectious Disease Journal2019-07-1566 citations

Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients

Antimicrobial Agents and Chemotherapy2016-08-0958 citations